subject: Global Cancer Biomarkers Market (2010 - 2015) [print this page] Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.
Biomarker are chemical, physical, or biological parameters that can be used to indicate disease states. Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.
The oncology biomarkers market offers high-growth opportunities with the numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) ) are have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs
Market Estimates and Forecasts
The report categorizes the Global oncology biomarkers market as follows:
Oncology biomarkers discovery market
Oncology biomarkers diagnostics market
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 15 company profiles for each of its sub-segments.
